Phase 2 CagriSema in T2D (Frias et al., 2023): CagriSema produced superior weight loss and glycemic improvement vs either monotherapy over 32 weeks
But what if GLP-1 drugs could offer another way out
Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus
Elsewhere on the internet I have read about research into the efficacy of Acetyl L-Carnitine and R-Lipoic Acid in enhancing the mitochondria function in rats, resulting in old rats performing like much younger rats
Current opinion in clinical nutrition and metabolic care, 26(6), 521527
large-scale randomised controlled trials specifically designed to assess cognitive outcomes are still ongoing Uncertainty about mechanisms : It remains unclear whether any cognitive effects result from direct brain effects, improved metabolic control, or other factors Population specificity : Most research has focused on individuals with type 2 diabetes